Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc.

NASDAQ:ALZN

Overview | Financials
Company Name Alzamend Neuro, Inc.
Symbol ALZN
Currency USD
Price 1.15
Market Cap 6,247,720
Dividend Yield 0%
52-week-range 1.06 - 15.06
Industry Biotechnology
Sector Healthcare
CEO Mr. Stephan Jackman
Website https://www.alzamend.com

An error occurred while fetching data.

About Alzamend Neuro, Inc.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder,

Related Stocks

Adverum Biotechnologies, Inc. logo

Adverum Biotechnologies, Inc.

ADVM

4.74 USD

Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc.

XLO

1.11 USD

HOOKIPA Pharma Inc. logo

HOOKIPA Pharma Inc.

HOOK

2.03 USD

Cytosorbents Corporation logo

Cytosorbents Corporation

CTSO

0.838 USD

Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc.

LUCD

0.775 USD

Tabula Rasa HealthCare, Inc. logo

Tabula Rasa HealthCare, Inc.

TRHC

10.5 USD

Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc.

PBYI

2.81 USD

Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc.

CAPR

14.13 USD

PAVmed Inc. logo

PAVmed Inc.

PAVM

0.645 USD

Financials

Numbers are in millions USD

Numbers are in millions USD